Advertisement

Topics

Metabolic tumour volume and response to therapy in diffuse large B cell lymphoma.

08:00 EDT 1st April 2019 | BioPortfolio

Summary of "Metabolic tumour volume and response to therapy in diffuse large B cell lymphoma."

No Summary Available

Affiliation

Journal Details

This article was published in the following journal.

Name: Hematological oncology
ISSN: 1099-1069
Pages:

Links

DeepDyve research library

PubMed Articles [43458 Associated PubMed Articles listed on BioPortfolio]

Liquid biopsy in tissue-born lymphomas.

In the era of personalised medicine, genetic information is critical to directing therapeutic options, aiding risk stratification and disease monitoring of lymphomas. Liquid biopsy is a novel noninvas...

The Role of Maintenance Therapy in Patients With Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.

Randomized trials of maintenance therapy (MT) in Diffuse Large B-cell Lymphoma (DLBCL) are inconclusive regarding its effect on overall survival (OS) and disease control. We aimed to examine the effic...

Prognostic value of metabolic tumour volume and total lesion glycolysis measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography in small cell lung cancer: A systematic review and meta-analysis.

The aim of this study was to evaluate the prognostic value of metabolic tumour volume (MTV) and total lesion glycolysis (TLG) for small cell lung cancer (SCLC).

Oncologist Volume and Outcomes in Older Adults Diagnosed With Diffuse Large B Cell Lymphoma.

Although provider-level volume is frequently associated with outcomes in cancers requiring complex surgeries, whether similar relations exist for cancers treated primarily with systemic therapy is unk...

Shiga-like toxin I exerts specific and potent anti-tumour efficacy against gastric cancer cell proliferation when driven by tumour-preferential Frizzled-7 promoter.

Tumour-targeted gene therapy is a promising approach for effective control of gastric cancer cell proliferation. Our study aims to develop a cancer therapy which combines tumour-targeting promoters wi...

Clinical Trials [19966 Associated Clinical Trials listed on BioPortfolio]

Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma

This trial studies how well nanochip technology (immuno-tethered lipoplex nanoparticle [ILN] biochip) works in monitoring treatment response and in detecting relapse in participants with d...

A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable

This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL) immunochemotherapy in participan...

Risk Adapted Therapy in Diffuse Large B Cell Lymphoma

This randomized phase II trial is studying two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell lymphoma.

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The purpose of this study is to assess the efficacy of TAK-659 measured by independent radiologic review committee (IRC)-assessed overall response rate (ORR) in participants with relapsed ...

Observation in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Treated on Clinical Trial CAN-NCIC-LY9

RATIONALE: Treatment for diffuse large B-cell non-Hodgkin's lymphoma may cause side effects and secondary cancers later in life. An observational study that evaluates patients after underg...

Medical and Biotech [MESH] Definitions

Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.

B-cell lymphoid tumors that occur in association with AIDS. Patients often present with an advanced stage of disease and highly malignant subtypes including BURKITT LYMPHOMA; IMMUNOBLASTIC LARGE-CELL LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; and DIFFUSE, LARGE B-CELL, LYMPHOMA. The tumors are often disseminated in unusual extranodal sites and chromosomal abnormalities are frequently present. It is likely that polyclonal B-cell lymphoproliferation in AIDS is a complex result of EBV infection, HIV antigenic stimulation, and T-cell-dependent HIV activation.

The response of cells in sensing a difference in OSMOTIC PRESSURE between the inside and outside of the cell. This response includes signaling from osmotic sensors to activate transcription factors, which in turn regulate the expression of osmocompensatory genes, all functioning to maintain CELL VOLUME and the water concentration inside the cells.

Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site.

The dynamic collection of metabolites which represent a cell's or organism's net metabolic response to current conditions.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Searches Linking to this Article